louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06812741: Duration of Postop Analgesia After Inguinal Hernia Surgery Treated with TAP Block Vs II/IH Nerve Block
Official title: Comparison of Mean Duration of Postoperative Analgesia in Patients Undergoing Inguinal Hernia Surgery Treated with Transversus Abdominal Plane Block Vs Ilioinguinal and Iliohypogastric Nerve Blocks
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Postoperative Analgesia
Keywords: postop analgesia
postoperative analgesia
TAP block
transversus abdominis plane block
ilioinguinal/ iliohypogastric nerve block
ilioinguinal/iliohypogastric nerve block
inguinal hernia surgery
abdominal nerve block
nerve block
nerve blocks
bupivacaine
ultrasound guided nerve block
ultrasound guided nerve blocks
0.25% bupivacaine
0.25 percent bupivacaine
hernioplasty
internal oblique
transversus abdominis
IIN
IHN
IIN/ IHN
II/ IH nerve block
transversus abdominis muscle
ilioinguinal muscle
iliohypogastric muscle
Lead sponsor: Pakistan Navy Station Shifa Hospital
Sponsor class: OTHER
First posted: 2025-02-06
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Comparing Postop Analgesia after Inguinal Hernia Surgery treated with TAP Block Vs Ilioinguinal/ Iliohypogastric Nerve Block

Detailed description: Comparison of Mean Duration of Postoperative Analgesia in Patients undergoing Inguinal Hernia Surgery treated with Transversus Abdominal Plane Block Versus Ilioinguinal/ Iliohypogastric Nerve Block

Eligibility criteria: Inclusion Criteria:

* Patients giving written informed consent
* Patients undergoing Inguinal Hernia surgery
* patients with ages 18-60 years
* ASA 1 and 2 patients

Exclusion Criteria:

* INR \> 1.0 (patients with bleeding tendency)
* EF \< 45 % (patients with cardiac dysfunction)
* FEV1 \< 80 % of normal (patients with pulmonary dysfunction)
* patients with renal disease

Primary outcomes:
measure: Mean duration of Postoperative Analgesia
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Combined Military Hospital Lahore
state: Punjab
Study officials:
References:
Clinical trial NCT05706441: Lung and Diaphragm Ultrasound Evaluation During Weaning From Mechanical Ventilation in COVID-19 Patients
Official title: Lung and Diaphragm Ultrasound Evaluation During Weaning From Mechanical Ventilation in COVID-19 Patients：A Prospective, Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Weaning
COVID-19
Lung Ultrasound
Diaphragm Ultrasound
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2023-01-31
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: admission to a COVID-19 ICU with hypoxemic respiratory failure； start of weaning from mechanical ventilation

Brief summary: The goal of this observational study is to learn about the function of lung and diaphragm ultrasound during weaning from mechanical ventilation in COVID-19 patients. The aim of this study was that the lung ultrasound score and diaphragm muscle mobility could be a potential predictive factor of weaning success.


Eligibility criteria: Inclusion Criteria:

* age \> 18 years,
* critically ill patients with COVID-19 (defined as those requiring mechanical ventilation due to respiratory failure), and eligible for their first SBT according to the attending physician's judgement that the underlying disease which led to intubation had sufficiently resolved.

Exclusion Criteria:

* patients with previous cardiothoracic surgery or pleurodesis and patients who presented with stridor (due to upper airway involvement) as a cause of extubation failure
* neuromuscular disease

Primary outcomes:
measure: The primary end-point was to verify the lung and diaphragm ultrasound evaluation if the predicts weaning success/failure from mechanical ventilation
timeFrame: spontaneous-breathing trial started until 48 hours following extubation
Secondary outcomes:
measure: The secondary outcome was to verify the predictive value of the traditional weaning parameters
timeFrame: spontaneous-breathing trial started until 48 hours following extubation
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: The Second Affiliated Hospital of Zhejiang University anesthesiology department
state: Zhejiang
Study officials:
References:
Clinical trial NCT06591741: PCA Administration in Prosthetic Joint Infection
Official title: Effects of Dietary Protocatechuic Acid (PCA) on the Function and Structure of Participants With Knee Prosthetic Joint Infection (PJI) as Measured by Standard Biomarkers
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Prosthetic Joint Infection
Lead sponsor: Dr. Dean Reeves Clinic
Sponsor class: OTHER
Collaborators: name: Lanny Johnson, M.D.
name: Leo Whiteside, M.D.
First posted: 2024-09-19
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Determine if dietary protocatechuic acid (PCA) will affect health biomarkers in patient undergoing revision surgery for a knee prosthetic joint infection

Detailed description: Patients who are scheduled to undergo revision surgery for a knee prosthetic joint infection are given PCA prior to surgery for a time period determined by a previous pilot study. PCA is then post-operatively until anticoagulation is stopped, and then will be resumed for four years post revision surgery. Measurement of changes in glucose control, immunity, will be measured over the first 3 months post-revision, and the post-revision reinfection rate over the full 4 years will be compared to a cohort rate

Eligibility criteria: Inclusion Criteria:

* 3 weeks or more after total knee arthroplasty
* One or more symptoms of infection, including redness, swelling, pain, increasing range of motion loss, fever, nausea, and loss of appetite.
* WBC count of aspirate \>50,000 cells per μL

Exclusion Criteria:

* Not willing to undergo blood draw at 3 months.

Primary outcomes:
measure: Change in immunity factor CXCL9 from 0 to 3 months
timeFrame: 0 and 3 months
measure: Change in HbA1c from 0 to 3 months
timeFrame: 0 and 3 months
Secondary outcomes:
measure: Reinfection rate after revision for prosthetic joint infection
timeFrame: 0 to 4 years
Other outcomes:
Locations:
Study officials:
affiliation: K. Dean Reeves, M.D., P.A.
name: Kenneth D Reeves, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00285441: Identification of Cytokine Profiles and T Cell Subsets Among Immunosuppressed Patients at Risk of Developing Active Tuberculosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Tuberculosis
HIV Infections
Rheumatoid Arthritis
Keywords: HIV
Lead sponsor: Hvidovre University Hospital
Sponsor class: OTHER
Collaborators: name: Copenhagen Hospital Corporation
name: The Danish Rheumatism Association
name: Danish Lung Association
First posted: 2006-02-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: The purpose of this study is to identify differences in TB specific immune responses among immunosuppressed patients latently infected with TB and patients with active TB.

Detailed description: Immunosuppressed patients latently infected with TB are at higher risk of developing active TB than patients with normal immune functions. Especially two patient categories are at risk: HIV positives and patients receiving TNF-a blocking medication. Existing methods of diagnosis and surveillance of latent TB infection can not identify who will develop active TB and who can control the infection. There is a need for better understanding of TB specific immune functions,as we believe deficient TB specific immune reactions is a key in reactivation of latent TB infection.

In this study we follow groups of latent TB infected patients with either rheumatoid arthritis or HIV. We follow the patients during treatment with TNF-a blocking medication, HAART treatment or prophylactic TB medication. Results are correlated to patients with active TB, latent TB and healthy controls.

Eligibility criteria: Inclusion Criteria:

* Latent TB infection + rheumatid arthritis
* Latent TB infection + HIV
* Active TB

Exclusion Criteria:

* Age \< 18yrs
* Pregnancy
* Patients not able to understand the given information

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Infectious disease department University Hospital Hvidovre
Study officials:
affiliation: University Hospital Hvidovre
name: Morten Ruhwald, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04379141: Ultrasonic Measurement of IVC and IJV in Predicting Hypotension After Anesthesia Induction
Official title: Ultrasonic Measurement of Inferior Vena Cava and Internal Jugular Vein in Predicting Hypotension After Anesthesia Induction in Patients Undergoing Gastrointestinal Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Anesthesia
Lead sponsor: Xuzhou Medical University
Sponsor class: OTHER
First posted: 2020-05-07
Enrollment: 150
Sex: ALL
Minimum age (years): 60
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients undergoing gastrointestinal surgery in the Affiliated Hospital of Xuzhou Medical University

Brief summary: This research is expected to study ultrasonic measurement of internal jugular vein and inferior vena cava, which can be used as a good index to predict hypotension after anesthesia induction, and its measurement method is simple and quick.

Detailed description: The induction of anesthesia is the process from the physiological state to the anesthetic state in a short period of time. Hypotension after anesthesia induction is closely related to many organ injuries. Gastrointestinal surgery patients' prohibition of fasting is an important mechanism of severe hypotension after anesthesia induction. At present, ultrasonic measurement of inferior vena cava and internal jugular vein has been proved to be a convenient and non-invasive means to evaluate patients' blood volume. The purpose of this research was to study the relativity between ultrasonic measurement of inferior vena cava and internal jugular vein and hypotension after anesthesia induction in patients.

Eligibility criteria: Inclusion Criteria:

* Gastrointestinal surgery
* BMI 18\~24
* ASA score gradeⅠ\~ III

Exclusion Criteria:

* anemia
* cirrhosis
* Emergency surgery
* severe hypertension
* New York Heart Association III \~ IV or ejection fraction \<40%
* cirrhosis
* Other serious systemic diseases

Primary outcomes:
measure: Incidence of hypotension after anesthesia Induction
timeFrame: within 12 hours after anesthesia induction
Secondary outcomes:
measure: Ultrasonic measurement of inferior vena cava and internal jugular vein
timeFrame: within 1 hour before anesthesia induction
Other outcomes:
Locations:
Study officials:
affiliation: The Affiliated Hospital of Xuzhou Medical University
name: Jin Dong Liu
role: STUDY_DIRECTOR
References:
Clinical trial NCT06416241: Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion
Official title: Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Retinal Vein Occlusion
Vascular Occlusive Disease
Keywords: optical coherence tomography angiography
aflibercept
retinal vein occlusion
biomarkers
Lead sponsor: University of Athens
Sponsor class: OTHER
First posted: 2024-05-16
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Central retinal vein occlusion (CRVO) is a common retinal vascular disorder, occurring when there is a blockage to the main blood vessel that transports blood away from the retina. CRVO may cause visual impairment, especially due to macular edema (swelling of the macula due to fluid accumulation) and macular non-perfusion.

Aflibercept has been found to improve visual acuity and reduce macular thickness in pivotal trials.

The purpose of this study was to evaluate the efficacy and safety of intravitreal aflibercept in real-world, using a patient-fitted treatment regimen. Additionally, imaging parameters have been assessed before and after treatment with intravitreal aflibercept.


Eligibility criteria: Inclusion Criteria:

* Treatment naive center-involved macular edema secondary to CRVO for no longer than 3 months.
* Patients \>18 years of age, who are diagnosed with macular edema secondary to CRVO who are scheduled to be treated with intravitreal aflibercept in real-life conditions
* BCVA of Snellen of 20/40 to 20/200 in the study eye

Exclusion Criteria:

* Previous PRP or macular laser photocoagulation in the study eye.
* Any prior ocular treatment in the study eye for macular edema secondary to CRVO.
* Prior systemic anti-VEGF or corticosteroid therapy, within the last 3 months before enrollment to the study.
* Any active or previous inflammation, ocular trauma
* Uncontrolled glaucoma (IOP\>30 mmHg)

Primary outcomes:
measure: Change in visual acuity as measured using ETDRS charts
timeFrame: 5 years
measure: Change in retinal thickness as measured in μm using spectral domain optical coherence tomography
timeFrame: 5 years
Secondary outcomes:
measure: Change in microvascular parameters in OCT angiography (vessel density, FAZ area)
timeFrame: 2 years
measure: Complications
timeFrame: 5 years
measure: Change in endothelial dysfunctionafter aflibercept treatment, as measured by the perfused boundary region sublingual 5-25 μm
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05511441: Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw
Official title: Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw Before Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Aspirin Sensitivity
Surgery
Keywords: Aspirin
Minimally Invasive Thoracic Surgery
Safety
Lead sponsor: The Second Hospital of Shandong University
Sponsor class: OTHER
First posted: 2022-08-23
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Surgeons are increasingly confronted by patients on long-term low-dose acetylsalicylic acid (ASA). However, the perioperative management of these patients undergo non-cardiac surgery has not yet been clear. This single- arm study was to evaluate the safety of continuous use of ASA in the perioperative period in routine minimally thoracic surgery.


Eligibility criteria: Inclusion Criteria:

1. patients with stage I-IIIa Non-small-cell Lung Cancer underwent radical resection or other benign lung lesions need Minimally Invasive Thoracic Surgery;
2. VATS and robotic surgery are both permitted;
3. cardio-pulmonary function can tolerate surgery.

Exclusion Criteria:

1. cardio-pulmonary function couldn't tolerate surgery;
2. high bleeding risk after the pre- operative evaluation.

Primary outcomes:
measure: bleeding volume
timeFrame: on the surgery day
measure: surgery time
timeFrame: on the surgery day
measure: postoperative drainage volume
timeFrame: within 7 days after surgery
measure: postoperative drainage duration
timeFrame: within 7 days after surgery
measure: postoperative hospitalization time
timeFrame: within 7 days after surgery
measure: postoperative complication rate
timeFrame: within 14 days after surgery
Secondary outcomes:
measure: progression- free survival
timeFrame: within 5 years after surgery
measure: overall survival
timeFrame: within 10 years after surgery
Other outcomes:
Locations:
city: Jinan
country: China
facility: The Second Hospital Of Shandong Univercity
state: Tianqiao
Study officials:
affiliation: The Second Hospital of Shandong University
name: Xiaogang Zhao
role: STUDY_DIRECTOR
References:
Clinical trial NCT02959034: Pediatric Metabolism and Microbiome Repository
Official title: Pediatric Metabolism and Microbiome Repository
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pediatric Obesity
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2016-11-08
Enrollment: 486
Sex: ALL
Minimum age (years): 10
Maximum age (years): 23
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Samples will be collected upon consent from the patient poplation of the Healthy Lifestyles Program at Duke for the care of children with obesity, a sibling of a patient in the Healthy Lifestyles Program, or is a patient at Duke Children's Primary Care.

Brief summary: The aim of this project is to establish a bio-repository of diverse specimen types to provide investigators access to specimens in order to further research related to metabolism and the microbiome in the pediatric population.

Detailed description: Human microbial cell lines, stool and/or DNA and RNA will be collected from participants 10-18 years with a BMI greater than 95th percentile and their healthy siblings.

Specimens will be collected at 3 time points over a seven month period. Healthy siblings will provide just one blood and stool sample. Samples will be maintained at the Duke Medical Science Research Laboratory.

Eligibility criteria: Inclusion Criteria:

* Patients of the Healthy Lifestyles Program at Duke for the care of children with obesity, a sibling of a patient in the Healthy Lifestyles Program, or is a patient at Duke Children's Primary Care.

Exclusion Criteria:

* Pregnant females.

Primary outcomes:
measure: The measure of abnormal metabolism using a sample biorepository
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Health System
state: North Carolina
Study officials:
affiliation: Duke University
name: Sarah C Armstrong, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05224934: Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma
Official title: Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Primary and Relapsed Retroperitoneal Sarcoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Soft Tissue Sarcoma
Retroperitoneal Sarcoma
Radiotherapy Side Effect
Ultra-hypofractionated Radiotherapy
Stereotactic Ablative Radiotherapy
Keywords: stereotactic ablative radiotherapy
hypofractionated radiotherapy
retroperitoneal sarcoma
soft tissue sarcoma
peri-operative complications
Lead sponsor: ChineseAMS
Sponsor class: UNKNOWN
First posted: 2022-02-04
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy followed by surgery for retroperitoneal sarcoma


Eligibility criteria: Inclusion Criteria:

* Primary soft tissue sarcoma of retroperitoneal or infra-peritoneal spaces of pelvis
* Sarcoma not originated from bone structure, abdominal or gynecological viscera
* All disease can be included safely within one radiotherapy field
* Absence of extension through the sciatic notch or across the diaphragm
* Histologically proven, excluding the following subtypes: Gastro-intestinal stromal tumors (GIST), rhabdomyosarcoma, PNET or other small round blue cells sarcoma, osteosarcoma or chondrosarcoma, aggressive fibromatosis, sarcomatoid or metastatic carcinoma
* ECOG performance status 0 to 2
* American Society of Anesthesiologist (ASA) score ≤2
* Normal renal function: Calculated Creatinine Clearance ≥50ml/min（by Cockcroft-Gault formula）and functional contralateral kidney by differential renal isotope scan
* Normal bone marrow and hepatic function.
* Contraception was needed for female patients of child-bearing age, or male patients whose partner had child-bearing age
* expected life expectancy longer than 5 years
* Written consent form was given prior to treatment
* Can safely be treated by radiotherapy and surgery

Exclusion Criteria:

* metastatic disease
* Tumor was previously treated by radiotherapy
* Involvement of liver, pancreatic head or duodenum

Primary outcomes:
measure: Peri-operative complications
timeFrame: From surgery date up to 7 days later
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences
state: Beijing
Study officials:
affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
name: Ning-Ning Lu
role: PRINCIPAL_INVESTIGATOR
References: